Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Neurology and Therapy|February 9, 2017
Number Needed to Treat in Multiple Sclerosis Clinical TrialsMacaulay Okwuokenye, Annie Zhang, Amy Pace, et al.
Neurology and Therapy|August 4, 2017
Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRMRobert J Fox, Ralf Gold, J Theodore Phillips, et al.
Clinical Therapeutics|November 25, 2018
Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational StudyKiren Kresa-Reahl, Pavle Repovic, Derrick Robertson, et al.
Clinical Therapeutics|July 29, 2017
Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRMÓscar Fernández, Gavin Giovannoni, Robert J Fox, et al.
Clinical Therapeutics|October 16, 2014
Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studiesMariko Kita, Robert J Fox, Ralf Gold, et al.
Multiple Sclerosis and Related Disorders|March 11, 2018
Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY)Stanley L Cohan, Harold Moses, Jonathan Calkwood, et al.
Pageof 1